U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07889284) titled 'Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout' on Oct. 15.
Brief Summary: This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Gout Disease
Intervention:
DRUG: Combined metabolic activators
A total of 20g of CMA2 with strawberry aroma and colouring ...